Advisory Research’s Halozyme HALO Stock Holding History

Advisory Research’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-41,420	Closed	-$2.36M	–	379
2022 Q4	$2.36M	Buy	41,420 +3,505	+9%	+$179K	0.22%	73
2022 Q3	$1.5M	Buy	37,915 +2,360	+7%	+$104K	0.15%	114
2022 Q2	$1.56M	Buy	+35,555	New	+$1.54M	0.15%	103

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Advisory Research's HALO Position: Q1 2023 in Review

Advisory Research sold out of Halozyme (HALO) in Q1 2023, closing a stake of 41,420 shares — an estimated $2.36M sold.

Advisory Research first reported a position in HALO in Q2 2022 and held it in 3 quarters. The position peaked at $2.36M in Q4 2022. 386 funds tracked by Wall St. Rank hold HALO as of Q1 2023.

Advisory Research reported no remaining Halozyme position as of Q1 2023 after selling out during the quarter.
Advisory Research sold 41,420 Halozyme shares in Q1 2023, an estimated $2.36M.
Advisory Research first reported a position in Halozyme in Q2 2022 and held it in 3 quarters.
Advisory Research's Halozyme position peaked at $2.36M in Q4 2022.
386 funds tracked by Wall St. Rank held Halozyme as of Q1 2023.

Based on Advisory Research's 13F filing for Q1 2023, filed 12 May 2023.